Reversing melanoma Cross-Resistance to BRAF and MEK inhibitors by Co-Targeting the AKT/mTOR pathway

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Atefi, Mohammad ^a   von Euw, Erika ^a   Attar, Narsis ^a   Ng, Charles ^a   Chu, Connie ^a   Guo, Deliang ^b   Nazarian, Ramin ^a   Chmielowski, Bartosz ^a   Glaspy, John A ^a   Comin Anduix, Begonya ^a,b   Mischel, Paul S ^a,b   Lo, Roger S ^a   Ribas, Antoni ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RO 5185426; SELUMETINIB; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VEMURAFENIB; BENZIMIDAZOLE DERIVATIVE; BRAF PROTEIN, HUMAN; CARRIER PROTEIN; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RICTOR PROTEIN, HUMAN; S6 KINASE; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CANCER RESISTANCE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MELANOMA CELL; MOLECULARLY TARGETED THERAPY; ONCOGENE N RAS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; IC 50; METABOLISM; MUTATION; TUMOR CELL LINE;

BENZIMIDAZOLES; CARRIER PROTEINS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MAP KINASE SIGNALING SYSTEM; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES; RNA, SMALL INTERFERING; SIROLIMUS; SULFONAMIDES; TOR SERINE-THREONINE KINASES;

EID: 83355170673     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028973     Document Type: Article

References (30)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
2. Gray-Schopfer V, Wellbrock C, Marais R, (2007) Melanoma biology and new targeted therapy. Nature 445: 851-857.
3. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
4. Weinstein IB, Joe AK, (2006) Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3: 448-457.
5. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, et al. (2010) Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Journal of Clinical Oncology 28: 611s.
6. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG, (2006) Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 126: 154-160.
7. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, et al. (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5: 1136-1144.
8. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599.
9. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine 364: 2507-2516.
10. Ribas A, Kim K, Schuchter L, Gonzalez R, Pavlick AC, et al. (2011) BRIM-2: An Open-label, multicenter Phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. Journal of Clinical Oncology 29: Abstr 8509.
11. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, et al. (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68: 4853-4861.
12. Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, et al. (2010) Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 102: 1724-1730.
13. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
14. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695.
15. Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, et al. (2010) Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032. J Transl Med 8: 39.
16. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, et al. (2009) The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A 106: 12932-12937.
17. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
18. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, et al. (2010) 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18: 39-51.
19. Grammer TC, Blenis J, (1997) Evidence for MEK-independent pathways regulating the prolonged activation of the ERK-MAP kinases. Oncogene 14: 1635-1642.
20. Rexer BN, Ghosh R, Arteaga CL, (2009) Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clin Cancer Res 15: 4518-4520.
21. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972.
22. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, et al. (2011) Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. Journal of clinical oncology: official journal of the American Society of Clinical Oncology.
23. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
24. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, et al. (2011) PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression. Cancer research 71: 2750-2760.
25. Jiang CC, Lai F, Thorne RF, Yang F, Liu H, et al. (2010) MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720. Clin Cancer Res.
26. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356.
27. Smalley KS, Lioni M, Herlyn M, (2006) Life isn't flat: taking cancer biology to the next dimension. In vitro cellular & developmental biology Animal 42: 242-247.
28. Shao Y, Aplin AE, (2010) Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer research 70: 6670-6681.
29. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, et al. (2004) Deregulated Akt3 activity promotes development of malignant melanoma. Cancer research 64: 7002-7010.
30. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, et al. (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer research 70: 8736-8747.